Sunshine Biopharma authorizes reverse split up to 1-for-20

Rhea-AI Filing Summary

Sunshine Biopharma Inc. (SBFM) reports that on September 15, 2026, its chief executive officer, Dr. Steve N. Slilaty, acting as holder of a majority of the voting power, approved by written consent an authorization for the board to implement a reverse split of the company’s common stock at a ratio of up to 1-for-20. The board has discretion whether to implement the reverse split and to set the exact whole-number ratio up to 1-for-20. The shareholder consent becomes effective 20 days after a definitive information statement describing the action is mailed to stockholders.

Filing Explained

The approved action changes share-count mechanics only if implemented; the board controls whether and at what ratio it occurs.

The filing records authorization for a possible reverse split, not a completed split: if used, it would consolidate common shares and proportionally raise the per-share price.

The split itself does not change the company’s value, while the board still must decide whether to implement it and choose the whole-number ratio up to 1-for-20.

The approval came from the chief executive officer, who the filing says held approximately 97% of total voting power, making that holder’s consent sufficient for the reported authorization.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Maximum reverse split ratio: Up to 1-for-20 CEO voting power: Approximately 97% of total voting power Consent effectiveness period: 20 days +1 more

4 metrics

Maximum reverse split ratio Up to 1-for-20 Authorization for reverse split of common stock approved September 15, 2026

CEO voting power Approximately 97% of total voting power Voting control held by Dr. Steve N. Slilaty

Consent effectiveness period 20 days Becomes effective 20 days after mailing of definitive information statement

Consent approval date September 15, 2026 Date written consent was executed by Dr. Slilaty

Key Terms

reverse split, written consent, definitive information statement, emerging growth company

4 terms

reverse split financial

"to effect a reverse split of the Company’s common in a ratio of up to 1-for-20"

A reverse split is when a company reduces the number of its outstanding shares by combining several existing shares into one new share, so the price per share rises proportionally while the company’s overall value stays the same. Investors care because it can make a stock appear more respectable or meet exchange rules — like turning many small coins into a single larger bill — but it can also signal financial trouble and often affects trading liquidity and investor perception.

written consent regulatory

"approved by written consent authorizing the Company’s board of directors"

A written consent is a formal, signed document in which shareholders or directors approve a corporate action without holding a live meeting, similar to signing a petition instead of gathering in person. It matters to investors because it can speed decisions, create a clear legal record of approval, and affect control or governance outcomes — for example enabling changes that would otherwise require a vote at a meeting.

definitive information statement regulatory

"effective 20 days after the definitive information statement relating to such consent"

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What reverse stock split has Sunshine Biopharma (SBFM) authorized?

Sunshine Biopharma obtained written consent authorizing its board to effect a reverse split of common stock at a ratio of up to 1-for-20. The board may decide whether to implement the reverse split and, if so, choose the exact whole-number ratio up to that limit.

Who approved the reverse split authorization for SBFM?

The authorization was approved by Dr. Steve N. Slilaty, Sunshine Biopharma’s chief executive officer, through a written consent on September 15, 2026, acting as the holder of the majority of the voting power of the company’s stockholders.

How much voting power does SBFM’s CEO control?

Dr. Steve N. Slilaty holds approximately 97% of the total voting power of Sunshine Biopharma’s stockholders. This concentration of voting power enabled him to approve the reverse split authorization by written consent without a separate stockholder meeting.

When does the SBFM shareholder consent become effective?

The shareholder consent becomes effective 20 days after the definitive information statement relating to the consent is mailed to stockholders. The timing of this mailing will determine when the consented authorization is formally effective.

Is the reverse stock split for SBFM guaranteed to occur?

No. The filing states that the board of directors has discretion whether or not to effect the reverse split. It also has discretion to select the exact whole-number ratio, up to 1-for-20, if the reverse split is implemented.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:06 PM Accepted by SEC EDGAR 09/16/2026 - 04:05 PM Learn about SEC filing dates

false 0001402328 0001402328 2026-09-15 2026-09-15 0001402328 us-gaap:CommonStockMember 2026-09-15 2026-09-15 0001402328 SBFM:CommonStockPurchaseWarrantsMember 2026-09-15 2026-09-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 15, 2026

SUNSHINE BIOPHARMA INC.

(Exact name of registrant as specified in its charter)

Colorado	001-41282	20-5566275
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer ID No.)

333 Las Olas Way

CU4 Suite 433

Fort Lauderdale, FL 33301

(Address of principal executive offices) (Zip Code)

(954) 330-0684

(Registrant’s telephone number, including area code)

__________________

(Former name or former address, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock, par value $0.001	SBFM	The Nasdaq Stock Market LLC
Common Stock Purchase Warrants	SBFMW	The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On September 15, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent authorizing the Company’s board of directors to effect a reverse split of the Company’s common in a ratio of up to 1-for-20, with the board of directors having the discretion as to whether or not the reverse split is to be effected, and with the exact ratio of any reverse split to be set at a whole number up to 1-for-20 as determined by the board in its discretion. The shareholder consent will be effective 20 days after the definitive information statement relating to such consent is mailed to stockholders. Dr. Slilaty, who is the Company’s chief executive officer, holds approximately 97% of the total voting power of the Company’s stockholders.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 16, 2026	SUNSHINE BIOPHARMA INC.
	By: /s/ Dr. Steve N. Slilaty
	Name: Dr. Steve N. Slilaty, Chief Executive Officer

3

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.5 KB
• EX-101 XBRL DEFINITION FILE 26.0 KB
• EX-101 XBRL LABEL FILE 35.7 KB
• EX-101 XBRL PRESENTATION FILE 24.6 KB